Brain metastases are common in patients with non-small-cell lung cancer (NSCLC). The
efficacy of bevacizumab, an anti-vascular endothelial growth factor (VEGF) humanized …

Bevacizumab is effective for the treatment of non-small cell lung cancer (NSCLC). Ongoing
trials are exploring the safety of bevacizumab in patients with inactive, previously treated …

Brain metastases are frequently encountered in patients with non‑small‑cell lung cancer
(NSCLC) and are a significant cause of morbidity and mortality. Chemotherapy has been …

Patients with nonsquamous non–small cell lung cancer (nsNSCLC; largely lung
adenocarcinoma) are at high risk of developing brain metastases. Preclinical data …

Background: Bevacizumab is a recombinant humanized monoclonal antibody that obstructs
the vascular endothelial growth factor (VEGF) pathway. Despite its extensive employment in …

Lung cancer is the leading cause of cancer-related mortality worldwide, and non-small cell
lung cancer (NSCLC) accounts for about 85% of all new lung cancer diagnosis. The majority …

Background Bevacizumab was demonstrated to have efficacy in patients with non-small cell
lung cancer (NSCLC) and brain metastases. However, cerebral toxicities were a major …

Purpose: The phase II prospective, noncomparative BRAIN study (NCT00800202)
investigated efficacy and safety of bevacizumab in chemotherapy-naïve or pretreated …

This retrospective analysis evaluated the mechanism of bevacizumab plus chemotherapy
(BV+ CT) for preventing brain metastasis derived from lung cancer. From the total of 159 …

Background: Despite the large use of bevabizumab in the treatment of primary tumors of the
brain, there is only limited experience with brain metastases (BM) and no experience in the …